AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32466854
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 50,000-unit pearl weekly for 4 weeks prior to the operation
Trial: 34653566
Drug: Intelligent insole
RxNorm normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intelligent insole system with pressure-sensing insoles and digital watch, worn during all daily activity for 18 months.
Trial: 35193445
Drug: Intensive physiotherapy
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive physiotherapy (twice-daily)
Trial: 35193445
Drug: Standard physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard physiotherapy (once-daily)
Trial: 33433575
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg sodium nitrite
Trial: 33433575
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg sodium nitrite
Trial: 36104235
Drug: 25 mg/day
RxNorm normalized name: estradiol 0.025 MG/Day Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/day of empagliflozin
Trial: 36104235
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day of empagliflozin
Trial: 33009281
Drug: Topical bromfenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bromfenac (Yellox)
Trial: 33009281
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (bromfenac and dexamethasone)
Trial: 33150227
Drug: HIV/AIDS knowledge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV/AIDS knowledge assessment through a self‐administered questionnaire
Trial: 33058961
Drug: Per log
RxNorm normalized name: triamcinolone acetonide Injectable Suspension [Sano Log]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per log ng/mL higher serum leptin
Trial: 34807249
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group informed about 17 Japanese family policy benefits
Trial: 32073874
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL V. odorata syrup every 12 hours for 4 weeks
Trial: 32073874
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL placebo syrup every 12 hours for 4 weeks
Trial: 33857782
Drug: Heat treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat treatment
Trial: 36446551
Drug: Diet or
RxNorm normalized name: T-Diet Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet or medication
Trial: 35405352
Drug: PRN ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PRN ranibizumab or bevacizumab treatment
Trial: 32800078
Drug: Combination Nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination Nicotine Replacement Therapy (Nicotine Patch and Lozenge)
Trial: 36099501
Drug: Estetrol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estetrol (15 mg) and Drospirenone (3 mg)
Trial: 36099501
Drug: Ethinylestradiol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol (30 or 20 mcg) with Levonorgestrel (150 mcg)
Trial: 36099501
Drug: Ethinylestradiol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinylestradiol (30 or 20 mcg) with Drospirenone (3 mg)
Trial: 33152314
Drug: Dietary counseling
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary counseling plus 800 mg/day of docosahexaenoic acid (Group 1)
Trial: 33152314
Drug: Routine counseling
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine counseling plus 800 mg/day docosahexaenoic acid (Group 2)
Trial: 33152314
Drug: Dietary counseling
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary counseling plus 200 mg/day docosahexaenoic acid (Group 3)
Trial: 33152314
Drug: Routine counseling
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine counseling plus 200 mg/day docosahexaenoic acid (Group 4, control group)
Trial: 33234219
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (rewarmed to normal body temperature 36° to 37°C)
Trial: 34441888
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy treatment
Trial: 32820851
Drug: Psilocybin (230
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin (230 μg/kg p.o.)
Trial: 35234828
Drug: Combined Individual
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Individual and Group Schema Therapy (IGST)
Trial: 35234828
Drug: Predominantly Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predominantly Group Schema Therapy (PGST)
Trial: 34937613
Drug: CTZ (LSTR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTZ (LSTR antibiotic paste)
Trial: 35976802
Drug: Pulsed nonthermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed nonthermal shortwave (radiofrequency) electromagnetic field therapy (RecoveryRx) applied for up to 30 days
Trial: 35976802
Drug: Pulsed nonthermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed nonthermal shortwave (radiofrequency) electromagnetic field therapy
Trial: 34865333
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of warm acupuncture at back-shu points of five zang organs and escitalopram oxalate tablets (30 min each time, 5 times a week for 6 weeks)
Trial: 34865333
Drug: Escitalopram oxalate
RxNorm normalized name: Escitalopram Oxalate
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram oxalate tablets (administered orally every day for 6 weeks)
Trial: 34229509
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) supplemented with intensive principle-based correctional counseling (PBCC)
Trial: 32567734
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid 250 mg and oral ranitidine 150 mg twice daily, plus topical fluocinolone‐based combination cream (FbTC) once daily.
Trial: 32567734
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (calcium lactate and multivitamin) and topical fluocinolone‐based combination cream (FbTC) once daily.
Trial: 34182150
Drug: Budesonide Oral
RxNorm normalized name: budesonide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide Oral Suspension (BOS)
Trial: 32696598
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula (HFNC) therapy (2 L/kg/min)
Trial: 33162348
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg of intravenous morphine during anesthetic induction
Trial: 33162348
Drug: Conventional anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional anesthesia without morphine
Trial: 36428277
Drug: Moisturizer applied
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizer applied three times daily on one side of the face
Trial: 32321718
Drug: CPC634 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPC634 (75 mg/m2)
Trial: 32321718
Drug: Conventional docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional docetaxel (75 mg/m2)
Trial: 39233210
Drug: Colchicine 0.5
RxNorm normalized name: colchicine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg daily
Trial: 34743243
Drug: Silver-modified atraumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver-modified atraumatic restorative treatment (SMART) sealants
Trial: 36682889
Drug: Niacin treatment
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin treatment
Trial: 35437945
Drug: Crizotinib treatment
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib treatment with a low radiomics score
Trial: 34588809
Drug: High-frequency impulse
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency impulse therapy (HFIT)
Trial: 33828241
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation of iron (60 mg), folic acid (500 mcg), and cyanocobalamin (1000 mcg) for 90 days
Trial: 33828241
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation of iron, folic acid, and vitamin B12 for 90 days
Trial: 32465627
Drug: Hybrid thrombolytic
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid thrombolytic approach (hTL) using alteplase infused at 1mg/min followed by maintenance infusion at 1mg/hour, median total alteplase dose was 74mg (IQR 48, 90mg).
Trial: 34371880
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral vitamin A and D drops (1800 IU vitamin A and 600 IU vitamin D2) for 2 months
Trial: 36112723
Drug: Probiotics (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (one capsule per day for 3 months)
Trial: 34179971
Drug: Follitropin delta
RxNorm normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin delta (individualised fixed-dose regimen based on AMH level and body weight)
Trial: 34179971
Drug: Follitropin delta
RxNorm normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Follitropin delta (individualised fixed-dose regimen)
Trial: 32334541
Drug: Life Review
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life Review Therapy for Holocaust Survivors (LRT-HS) consisting of 20-25 sessions
Trial: 34870587
Drug: PAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAP therapy with ≥ 4 hours of use on ≥ 70% of nights
Trial: 34870587
Drug: PAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAP therapy with < 4 hours of use or < 70% of nights
Trial: 33374791
Drug: Clobetasol oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobetasol oral gel 0.05%
Trial: 34603442
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg intravenous before skin incision
Trial: 32075228
Drug: Enzogenol® 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzogenol® 50 mg
Trial: 32075228
Drug: Enzogenol® 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzogenol® 400 mg
Trial: 36760029
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received treatment including single surgery of bone grafting associated with periosteal releasing incision
Trial: 34313093
Drug: Critically important
RxNorm normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Critically important antimicrobials administered sub-therapeutically for prophylaxis and growth enhancement purposes.
Trial: 33710263
Drug: Menopausal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Menopausal hormone therapy (HT) including conjugated equine estrogens (E) alone for women without a uterus (n=560) and E plus medroxyprogesterone acetate (P) for those with an intact uterus (n=610)
Trial: 35577478
Drug: Continue DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue DMARD therapy after first dose vaccination
Trial: 35577478
Drug: Withhold DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withhold DMARD therapy after first dose vaccination
Trial: 35577478
Drug: Continue DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue DMARD therapy after second dose vaccination
Trial: 35577478
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no DMARD therapy)
Trial: 35577478
Drug: tsDMARD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tsDMARD therapy
Trial: 33974920
Drug: Pre-workout supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-workout supplement (SUPP)
Trial: 36477362
Drug: sequential belimumab
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: sequential belimumab + rituximab
Trial: 35524760
Drug: Breast nurse
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast nurse intervention including education, literacy material, empathetic counselling, phone call reminders, and monitoring of medication refill.
Trial: 34521217
Drug: Invasive management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive management (medical therapy + angiography and revascularization if feasible)
Trial: 34521217
Drug: Conservative approach
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative approach (medical therapy alone with revascularization if medical therapy failed)
Trial: 32986682
Drug: PF-06412562 (split
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06412562 (split dose 25+20mg)
Trial: 32667582
Drug: Short-course hyperthermic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course hyperthermic intraperitoneal chemotherapy (HIPEC) for 30 minutes
Trial: 33781259
Drug: Rehabilitation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation therapy including six levels of rehabilitation exercises
Trial: 33263702
Drug: Slow infusion
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow infusion speed (333mL/h)
Trial: 33263702
Drug: Rapid infusion
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid infusion speed (999mL/h)
Trial: 37845604
Drug: Drug-coated balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coated balloon (DCB) angioplasty
Trial: 35340225
Drug: Exercise prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise prescription (Control)
Trial: 35713670
Drug: Thymosin alpha
RxNorm normalized name: Thymosin alpha 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin alpha 1 (Tα1) 1.6 mg every 12 hours for the first 7 days and 1.6 mg once a day for the subsequent 7 days
Trial: 32462427
Drug: Intravenous autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous autologous bone marrow-derived MSCs
Trial: 32462427
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no MSC treatment)
Trial: 33545758
Drug: Anti-PD-1/PD-L1 agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1/PD-L1 agents
Trial: 34329774
Drug: Resmetirom 80
RxNorm normalized name: resmetirom 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resmetirom 80 mg daily
Trial: 34402728
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg drospirenone (DRSP)
Trial: 34402728
Drug: 0.075 mg
RxNorm normalized name: mestranol 0.075 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075 mg desogestrel (DSG)
Trial: 32485633
Drug: Hippotherapy (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hippotherapy (16 sessions of 30 minutes, twice a week for 8 weeks)
Trial: 32392952
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive surfactant administration (MISA)
Trial: 32392952
Drug: Endotracheal intubation
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endotracheal intubation surfactant administration (EISA)
Trial: 35039439
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with 0.4 mL/kg of 0.25% ropivacaine
Trial: 35039439
Drug: II/IH block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: II/IH block with 0.2 mL/kg of 0.25% ropivacaine
Trial: 35039439
Drug: QLB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLB with 0.4 mL/kg of 0.25% ropivacaine
Trial: 33947344
Drug: Ivermectin 200
RxNorm normalized name: ivermectin 200 ug / praziquantel 1.5 mg ORAL PASTE [Equimax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 200 mcg/kg/day for 5 days added to hydroxychloroquine + favipiravir + azithromycin
Trial: 33947344
Drug: Reference treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference treatment (hydroxychloroquine + favipiravir + azithromycin) without ivermectin
Trial: 33947344
Drug: Reference treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference treatment without ivermectin
Trial: 32616493
Drug: Self-administered questionnaires
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaires
Trial: 34521568
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D levels (intervention not specified in terms of dosage or duration)
Trial: 35295056
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment with premolar extraction
Trial: 35295056
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment without premolar extraction
Trial: 35578182
Drug: Fremanezumab treatment
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fremanezumab treatment
Trial: 35683437
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (AT) 3 times a week for 8 weeks.
Trial: 35569036
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1015550 (18 mg twice daily)
Trial: 33079921
Drug: Topical moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical moxifloxacin 0.5% plus CXL
Trial: 33079921
Drug: Topical moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical moxifloxacin 0.5%
Trial: 32927476
Drug: 30 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minutes of hypoglycemia (p-glucose < 2.9 mmol/L) followed by a euglycemic clamp
Trial: 34129728
Drug: Lidocaine/tetracaine 7%/7%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/tetracaine 7%/7% peel cream (L/T‐pC) applied 45 minutes before laser treatment
Trial: 34129728
Drug: Control (emollient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (emollient cream)
Trial: 33406977
Drug: Thyroid peroxidase
RxNorm normalized name: Thyroid peroxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid peroxidase antibodies (TPOAb)
Trial: 33406977
Drug: Thyroglobulin antibodies
RxNorm normalized name: thyroglobulin
DrugBank: Thyroglobulin (DB01584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroglobulin antibodies (TgAb)
Trial: 33235121
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with placebo
Trial: 35550716
Drug: Incisional negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incisional negative pressure wound therapy dressing
Trial: 33559444
Drug: Epidural nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural nerve block with 20 mL 0.375% ropivacaine 30 min before anesthesia induction
Trial: 33548080
Drug: LA-enriched diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA-enriched diet (sunflower oil, 30-50 mL, 62-63% LA)
Trial: 33548080
Drug: ALA-enriched diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALA-enriched diet (Camelina sativa oil, 30-50 mL, 30-35% ALA)
Trial: 32124625
Drug: Oxybutynin 5
RxNorm normalized name: oxyBUTYnin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 5 mg tablet twice a day for 3 months